AAM All Access Podcast - Featuring AAM CEO Dan Leonard and Apotex President and CEO Jeff Watson

FDA Acting Commissioner to Speak at GRx+Biosims

Dr. Janet Woodcock will bring invaluable insights on generics and biosimilars during this public health emergency. Sign up for GRx+Biosims 2021 now and enjoy $300 in savings.

Register Now
GRx+Biosims 2021

Hear the latest from top-in-their-field speakers and government officials, connect with peers from around the world and explore new learning tracks in the generics and biosimilars industry. November 8-10, 2021. Sign up for GRx+Biosims 2021 now and enjoy $300 in savings!
Watch Video
AAM All Access Podcast: Dan Leonard and Jeff Watson

Dan Leonard speaks with Apotex President and CEO Jeff Watson on the history and vision of the manufacturer and a future of “tremendous opportunity” for generics.

Listen to Podcast
Industry Response to COVID-19

The coronavirus (COVID-19) pandemic is disrupting everyday life around the world and imposing unprecedented stress on our health care system. Here are some responses and resources from the U.S. generics and biosimilars industry.

Learn More
New Generics Are Less Available in Medicare Than Commercial Plans

AAM releases a new report confirming Medicare Part D plans continue to fail to get new generics to patients.

Read Report
What We Know—and What We Don’t

In the past two decades, misunderstood and exaggerated stats regarding the generics supply chain have been cited.

View #RxFacts
Take With Confidence

Generic Prescription Drugs: Your Health. Our Commitment.

Learn More
Patient Stories: Voices of Access

AAM's Voices of Access report features patients across the country who tell the impact of accessible generic and biosimilar medicines.

Meet the AAM Patients
Health Care Savings, State by State

The average state saved $6.1 billion from the use of generic drugs in 2019. How much did your state save?

Read Blog

Working to leave a positive impact on...

Industry

We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers of generic and biosimilar medicines and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More

People

We measure our success as an industry by the lives we impact. We work to protect the low cost of generic and biosimilar medicines and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More

Policy

We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable generic and biosimilar medicines. Learn More

About Us

The Association for Accessible Medicines improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Recent Updates

Pharmacist talking to a patient at a pharmacy

Sep 21, 2021 | Rachel Schwartz

Study Finds U.S. Generic and Biosimilar Savings Totaled a Record $338 Billion in 2020

Sep 13, 2021 | Rachel Schwartz

Polly Webster Joins AAM As Vice President, Federal Affairs

Drug manufacture

Sep 13, 2021 | Rachel Schwartz

Scott Kuzner Joins AAM As Senior Director, Sciences and Regulatory Affairs

Press Release: HHS 45-Day Plan to Lower the Cost of Prescription Drugs

Sep 9, 2021 | Rachel Schwartz

AAM Statement on HHS 45-Day Plan to Lower the Cost of Prescription Drugs

Zydus Pharmaceuticals USA, Inc. headquarters located in Pennington, NJ.

Sep 2, 2021 | Jewel Smith

Quality, Innovation and Service: AAM Member Zydus USA

Video

Aug 30, 2021 | Erica Klinger

Join us a GRx+Biosims 2021 — Progress + Process